SYNERGEN APPOINTS NATIONAL SALES MANAGER
SYNERGEN APPOINTS NATIONAL SALES MANAGER BOULDER, Colo., May 4 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN)
announced today the appointment of R. Michael Smullen as national sales manager. This new position reflects the company's commitment to building a sales force in the United States to market Synergen products.
Based at company headquarters in Boulder, Smullen initially will be involved in the strategic planning and design for the sales force. This will include the design of sales force regional and territory alignments and integration of sales into the early process of drug development. As Synergen's first product, ANTRIL(TM) for sepsis syndrome, gets closer to receiving an FDA license for marketing, Smullen will recruit regional sales managers and begin to build the field sales force. Smullen joins Synergen from Fujisawa Pharmaceutical Co., where he held management positions at the district, division, regional and national level. At Fujisawa, Smullen was involved in the launch of a third generation cephalosporin for serious and life-threatening infections. Previously Smullen held sales positions at SmithKline &
French and Boehringer Ingelheim pharmaceutical companies.
Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein based pharmaceuticals. The company's research is targeted toward products to treat inflammatory diseases, chronic ulcers and neurological diseases. Synergen's lead product, ANTRIL, is in clinical testing for seven indications including sepsis syndrome, rheumatoid arthritis and graft vs. host disease. -0- 5/4/92 /CONTACT: Debra Catz Bannister of Synergen, 303-938-6242/ (SYGN) CO: Synergen Inc. ST: Colorado IN: MTC SU: PER
MC-BB -- DV001 -- 5809 05/04/92 08:04 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||May 4, 1992|
|Previous Article:||LEADING RESEARCHERS PRESENT PRECLINICAL RESULTS WITH THE LIPOSOME COMPANY'S TCL C-53|
|Next Article:||ROCKWELL INTERNATIONAL, HONEYWELL TEAM TO PURSUE MINUTEMAN III GUIDANCE REPLACEMENT PROGRAM|